The most important word in an AI approval is not "approved." It is the one that says how many humans are still reading.
On 5 October Nolla Health put out a two-minute film from a kitchen in Utah. Its co-founder and CEO, Luis Wenus, says the state has granted "the first US approval for an AI to prescribe a patient's medication from start to finish," that the AI can write a first prescription "all by itself," and calls it "the first ever end-to-end AI doctor." Acne, adults only, five dollars a month.
Utah's regulator publishes the agreement it signed with Nolla on 22 September. Two Utah licensed physicians review every prescription before it is sent. That is stage one. Stage two is review after the fact. Stage three is sampling. Each step up needs the regulator's written approval, and a monthly report shows how often the AI and the doctors agreed.
Both sentences are true. "All by itself" is the top of a ladder, and the pilot is standing on the first rung. The experiment is the climb, and for once the step sizes are written down in public.
Nolla's own medical adviser, who holds a stake and whose group does the reviewing, names the risk better than any critic: "prove it's safe and the scope quietly widens until the physician is a rubber stamp." His answer is that the scope "lives in a state agreement, not a product roadmap." Hold him to it. The number to watch is the agreement rate, 96% on the last thousand cases by his count, with a 95% floor in the rules.
Why it's Material. This is a risk story: the first AI allowed to prescribe is also the first with its supervision schedule published, and the rung it stands on today is the only honest description of what it is.
The Monday move. Find one AI in your company that decides something and ask which rung it is on: every output read before it goes out, read after, or sampled. If nobody can say, it is on the top rung by default, and nobody chose that.
Video: Nolla Health, official, 5 October 2026. Luis Wenus and Dr Zaid Fadul.
Monday Morning Mashup No. 141. What moved in AI, every Monday.
